Docivyx is a drug owned by Avyxa Holdings Llc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 14, 2036. Details of Docivyx's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10398785 | Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use |
Mar, 2036
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Docivyx's patents.
Latest Legal Activities on Docivyx's Patents
Given below is the list of recent legal activities going on the following patents of Docivyx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Sep, 2022 | US10398785 |
| Recordation of Patent Grant Mailed
Critical | 03 Sep, 2019 | US10398785 |
| Patent Issue Date Used in PTA Calculation
Critical | 03 Sep, 2019 | US10398785 |
| Issue Notification Mailed
Critical | 14 Aug, 2019 | US10398785 |
| Dispatch to FDC | 02 Aug, 2019 | US10398785 |
| Application Is Considered Ready for Issue
Critical | 18 Jul, 2019 | US10398785 |
| Issue Fee Payment Received
Critical | 17 Jul, 2019 | US10398785 |
| Issue Fee Payment Verified
Critical | 17 Jul, 2019 | US10398785 |
| Mail Notice of Allowance
Critical | 17 Apr, 2019 | US10398785 |
| Notice of Allowance Data Verification Completed
Critical | 16 Apr, 2019 | US10398785 |
US patents provide insights into the exclusivity only within the United States, but
Docivyx is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Docivyx's family patents as well as insights into
ongoing legal events
on those patents.
Docivyx's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Docivyx's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 14, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Docivyx Generic API suppliers:
Docetaxel is the generic name for the brand Docivyx. 16 different companies have already filed for the generic of Docivyx, with Mylan Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Docivyx's generic
Alternative Brands for Docivyx
There are several other brand drugs using the same active ingredient (Docetaxel) as Docivyx. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Docetaxel, Docivyx's active ingredient. Check the complete list of approved generic manufacturers for Docivyx
About Docivyx
Docivyx is a drug owned by Avyxa Holdings Llc. Docivyx uses Docetaxel as an active ingredient. Docivyx was launched by Avyxa Holdings in 2022.
Approval Date:
Docivyx was approved by FDA for market use on 22 November, 2022.
Active Ingredient:
Docivyx uses Docetaxel as the active ingredient. Check out other Drugs and Companies using Docetaxel ingredient
Dosage:
Docivyx is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG/2ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 160MG/16ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 80MG/8ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |